



IBA Signs Contract to Install Seventh Proteus®ONE Compact Proton Therapy Solution

Third Contract in France for IBA's Proton Therapy Solution Collaboration Agreement to Develop Carbon Therapy

Louvain-la-Neuve, Belgium, December 3rd, 2014 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract with CYCLHAD (a CYCLOtron for HADron Therapy) for the installation of its single-room proton therapy system Proteus®ONE* in Caen, France. The contract includes the delivery of the Proteus®ONE equipment as well as a 15 year maintenance agreement, which together will have a value of between EUR 43 and 48 million to IBA. The delivery of the equipment is expected to take place in 2017.

The contract represents the seventh installation of a Proteus®ONE. The Proteus®ONE system has been developed by IBA to allow more patients globally to access proton therapy. Proteus®ONE is a smaller, less expensive and faster to install solution, encompassing the latest in proton therapy technologies, including Pencil Beam Scanning.

In a second phase of the development of the center, IBA will collaborate with several French industrial partners and semi-public institutions, to develop the potential of carbon beam therapy. Within this collaboration, IBA will provide support and expertise for the development of a prototype carbon therapy system based on an advanced 400 MeV (megaelectron-volts) superconducting isochronous cyclotron able to accelerate carbon ions used in hadron therapy. Carbon ions have the same physical characteristics as protons, but also have the advantage of being particularly effective compared to other radiotherapy techniques for the treatment of radiation-resistant tumors.

Olivier Legrain, Chief Executive Officer of IBA commented: *“This contract reinforces the success of IBA’s new compact proton therapy solution, Proteus®ONE, which is simpler to install, operate, and finance. In addition, IBA is pleased to be collaborating with industrial partners and semi-public institutions in the French area of Basse-Normandie with the objective to improve treatment techniques that have the potential to improve patient health.”*

Daniel Guerreau, President of CYCLHAD, said: *“We are pleased to collaborate with IBA, the global leader in proton therapy that has the most experienced and talented team to develop the future of this unique technology. The signing of this contract with IBA also enables CYCLHAD to create in Caen a research center dedicated to hadron therapy and related technologies. Thanks to the Basse-Normandie region, this proton therapy center will be the third in France. Today, only 1% of the cancer patients treated by radiotherapy benefit from this unique technology. The need for proton therapy is*



largely superior, particularly to treat cancers for which it is important to preserve the healthy surrounding tissues and organs. These indications include eye, brain, spinal cord and pediatric cancers. We are very pleased to collaborate with IBA and industrial partners to develop a carbon ion accelerator that CYCLHAD wants to install during the second phase of the development of the center.”

Notes to Editors

About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life.

**Proteus[®] ONE is the brand name of a new configuration of the Proteus[®] 235.*

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About CYCLHAD

The operating company CYCLHAD has been created in 2010 in order to finance the hadron therapy project (proton therapy center, carbon solution development as a second step and the building and all related equipment) in Caen, France. IBA has recently invested €1.5 million as part of a capital increase of CYCLHAD and thereby becomes a 33.3% shareholder of the company, alongside with local associations and private investors, mobilized by the Basse-Normandie region.



For further information please contact:

IBA

Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
thomas.ralet@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Bielecka, Mary-Jane Elliott, Matthew Neal,
Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
IBA@consilium-comms.com